Veeva Systems Inc. (VEEV) reported a 16.7% year-over-year revenue increase for Q2 fiscal 2026, reaching $789 million, driven by strong performance in its Commercial and R&D segments. The company, which has a market capitalization of $46.89 billion, expects a 23.5% growth rate over the next five years. Year-to-date, Veeva’s shares have risen 36.9%, outperforming the industry’s 27.7% growth amidst a broader S&P 500 decline of 14.1%.
However, Veeva is facing rising operational costs, with general and administrative expenses up 56.1% year-over-year. Total operating expenses increased 17.3% for the quarter, and management anticipates continued increases due to hiring and expansion efforts. Despite this, the Zacks Consensus Estimate for Q3 fiscal 2026 revenues is $791.9 million, a 13.3% improvement year-over-year, with earnings per share estimated at $1.95, reflecting an 11.4% year-over-year increase.
Key partnerships, such as those with Gilead Sciences and IQVIA, further solidify Veeva’s position in the life sciences technology market.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
